98%
921
2 minutes
20
Behavioural treatments are recommended first-line for insomnia, but long-term benzodiazepine receptor agonist (BZRA) use remains common and engaging patients in a deprescribing consultation is challenging. Few deprescribing interventions directly target patients. Prescribers' support of patient-targeted interventions may facilitate their uptake. Recently assessed in the Your Answers When Needing Sleep in New Brunswick (YAWNS NB) study, Sleepwell (mysleepwell.ca) was developed as a direct-to-patient behaviour change intervention promoting BZRA deprescribing and non-pharmacological insomnia management. BZRA prescribers of YAWNS NB participants were invited to complete an online survey assessing the acceptability of Sleepwell as a direct-to-patient intervention. The survey was developed using the seven construct components of the theoretical framework of acceptability (TFA) framework. Respondents (40/250, 17.2%) indicated high acceptability, with positive responses per TFA construct averaging 32.3/40 (80.7%). Perceived as an ethical, credible, and useful tool, Sleepwell also promoted prescriber-patient BZRA deprescribing engagements (11/19, 58%). Prescribers were accepting of Sleepwell and supported its application as a direct-to-patient intervention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1017/S0714980824000114 | DOI Listing |
Pediatr Blood Cancer
September 2025
Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA.
Background: Screening for financial hardship and health-related social needs (HRSN) in pediatric oncology is recommended, yet practices vary widely, and standardized implementation remains limited. We implemented systematic screening in a pediatric oncology clinic in New York City.
Procedure: We evaluated the implementation of financial hardship (two items) and HRSN (difficulty affording food, housing, transportation, eight items) screening in outpatient pediatric oncology clinic.
Background: Digital health technologies can potentially improve clinical research efficiency and increase participant diversity but have challenges with long-term participant engagement.
Objectives: The Heartline Study evaluated the impact of a mobile app-based heart health engagement program with the Irregular Rhythm Notification (IRN) and electrocardiogram features of the Apple Watch on diagnosis, treatment, and outcomes of atrial fibrillation in U.S.
Clin Transl Sci
August 2025
Development Operations, AstraZeneca Global R&D (China) Co., Ltd, Shanghai, China.
The decentralized clinical trial (DCT) approach may potentially improve patient accrual and diversity and reduce logistical burden; however, its implementation in China is still in its infancy due to limited practical experience and guidance. We utilized stakeholder engagement research to simulate DCT processes and investigate their feasibility and applicability in a local context. This study, conducted between October 2023 and June 2024, engaged stakeholders to simulate the roles of the investigator, study nurse/pharmacist, and patient in a DCT, and explored feasibility, challenges, and procedures locally.
View Article and Find Full Text PDFTher Innov Regul Sci
June 2025
Chiesi Farmaceutici, S.P.A., Parma, Italy.
Background: Decentralized clinical trials (DCTs) are increasingly being used to enable greater participation of patients in clinical research and improve the patient experience. In 2021, the Chiesi research and development team established the Digital innovAtion for patieNt Centric hEalth (DANCE) initiative with the aim to enhance the clinical trial journey for participants by merging patient perspectives with modern technology. As part of this project, the concept of DCTs was explored with patients affected by respiratory or rare diseases and with healthcare professionals (HCPs) treating these patients in the USA and Europe.
View Article and Find Full Text PDFPEC Innov
June 2025
Heart and Vascular Center, Section of Cardiovascular Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Background: Familial hypercholesterolemia (FH) is a genetic condition which elevates cholesterol levels and increases risk of premature cardiac events. Medical treatment greatly reduces those risks. However, in the United States, FH is markedly underdiagnosed.
View Article and Find Full Text PDF